The Latest Cardiac and Vascular News
IRVINE, Calif., Sept. 28, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, today announced that it will present and meet with potential investors at The MicroCap Conference on October 1 and 2 at The Essex […]
IRVINE, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has completed and submitted its application to INVIMA (the Colombian equivalent of the US FDA) for approval of its […]
IRVINE, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, has commissioned a research report from The Sage Group, a research organization specializing in peripheral vascular disease. The report, titled “Chronic Venous Disease: Epidemiology […]
IRVINE, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in bioprosthetic medical devices that establish improved standards of care for treating cardiac and vascular diseases, today announced that it has received approval for the first-in-human testing of its VenoValve® bioprosthetic medical […]
IRVINE, Calif., July 24, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has received approval from the Ethics Committee at Fundación Santa Fe de Bogotá […]
IRVINE, Calif., July 13, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that Bob Rankin will be joining the company as its chief financial officer beginning July […]
IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has initiated an analysis of its bioprosthetic heart valve in order to determine […]
IRVINE, Calif., June 20, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has selected Fundación Santa Fe de Bogotá (“FSFB”), in Bogota Columbia, as the […]
IRVINE, Calif., June 05, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced the closing of its previously announced initial public offering of 1,500,000 units, each unit consisting of […]
IRVINE, Calif., May 31, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced the pricing of its initial public offering of 1,500,000 units, each unit consisting of one share […]
